论文部分内容阅读
目的 观察干扰素α- 1b治疗慢性乙型肝炎的临床疗效。方法 采用前瞻性对照研究方法 ,将符合纳入标准的 75例患者分为治疗组 (4 5例 )及对照组 (30例 )。治疗组采用干扰素α- 1b3MU或 5 MU,周 3次肌内注射给药 ,疗程 4～ 6月 ;对照组不使用干扰素等抗病毒药物及免疫调节剂 ,仅予保肝及对症处理。观察用药开始 (纳入随访 )后 6月时的临床疗效。结果 治疗组完全反应 13例 (2 8.88% ) ;部分反应 13例 (2 8.88% ) ;无反应 19例 (4 2 .2 2 % ) ,肝功基本复常者2 0例 (4 4.44 % )。治疗组 HBe Ag转阴 2 2例 (4 8.89% ) ,HBV DNA转阴 13例 (13/ 36 ,36 .15 % ) ;而对照组分别为 5例(16 .6 7% )及 2例 (2 / 2 5 ,8.0 0 % ) ,两组比较有显著性差异 (P<0 .0 1)。治疗组 HBs Ag阴转 1例 ,而对照组 HBs Ag无阴转。结论 干扰素对于符合纳入标准的部分病例有治疗作用。
Objective To observe the clinical efficacy of interferon α-1b in the treatment of chronic hepatitis B. Methods According to the prospective and controlled study, 75 patients who met the inclusion criteria were divided into treatment group (45 cases) and control group (30 cases). Interventional therapy with interferon α-1b3MU or 5 MU, intramuscular injection of 3 times a week, the course of 4 to 6 months; the control group does not use interferon and other antiviral drugs and immunomodulators, only to liver protection and symptomatic treatment. Clinical efficacy was observed at 6 months after the start of treatment (included in follow-up). Results There were 13 cases (21.88%) in the treatment group, 13 cases (28.88%) in the partial response group, 19 (4.22%) in the non-reaction group and 20 cases (4.44%) in the normal liver function group . In the treatment group, 23 (36.89%) were HBeAg negative and 13 (36.35%) were negative in the HBV DNA group, while 5 (16.67%) in the control group and 2 2/2 5, 8.0 0%), there was significant difference between the two groups (P <0.01). One case of HBs Ag was negative in the treatment group, while the other was negative in the control group. Conclusion Interferon has a therapeutic effect on some cases meeting the inclusion criteria.